Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-β signalling in COVID-19 survivors

Coronavirus disease 2019 (COVID-19) has rapidly spread around the world causing global public health emergency. In the last twenty years, we have witnessed several viral epidemics such as severe acute respiratory syndrome coronavirus (SARS-CoV), Influenza A virus subtype H1N1 and most recently Middl...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Life sciences (1973) 2021-02, Vol.266, p.118883-118883, Article 118883
Hauptverfasser:	P, Krishna Murthy, Sivashanmugam, Karthikeyan, Kandasamy, Mahesh, Subbiah, Rajasekaran, Ravikumar, Vilwanathan
Format:	Artikel
Sprache:	eng
Schlagworte:	Abnormalities Adult Aged Chloroquine Coronaviridae Coronavirus Infections - pathology Coronaviruses COVID-19 COVID-19 - complications COVID-19 - pathology COVID-19 - therapy Dexamethasone Drug Repositioning Epidemics Epigenetics Extracellular Matrix - pathology Extracellular Matrix - virology Fibrosis HDAC inhibitors Histone deacetylase Histone Deacetylase Inhibitors - pharmacology Histone Deacetylase Inhibitors - therapeutic use Histones Humans Infections Influenza A Inhibitors Lung diseases Lungs Middle Aged Middle East respiratory syndrome Molecular modelling Patients Public health Pulmonary fibrosis Pulmonary Fibrosis - drug therapy Pulmonary Fibrosis - virology Respiratory diseases Respiratory function Review Risk Factors SARS-CoV-2 Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Signal Transduction Survivors TGF-β Transforming Growth Factor beta - metabolism Viral diseases Viruses
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!